Pascal and Francis Bibliographic Databases


Search results

Your search

kw.\*:("Histone deacetylase inhibitor")


A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV


A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 1592

  • Page / 64


Selection :

  • and

Appraisal of GABA and PABA as linker: Design and synthesis of novel benzamide based histone deacetylase inhibitorsRAJAK, Harish; KUMAR, Pramod; PARMAR, Poonam et al.European journal of medicinal chemistry. 2012, Vol 53, pp 390-397, issn 0223-5234, 8 p.Article

A novel series of L-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: Design, synthesis and molecular modeling studyDAWEI HUANG; XIAOHUI LI; YINGDONG WEI et al.European journal of medicinal chemistry. 2012, Vol 52, pp 111-122, issn 0223-5234, 12 p.Article

Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLETBREST, Patrick; GUSTAFSSON, Mattias; MOSSBERG, Ann-Kristin et al.Cancer research (Baltimore). 2007, Vol 67, Num 23, pp 11327-11334, issn 0008-5472, 8 p.Article

A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasmaNINGNING ZHANG; BOON CHER GOH; YOK MOI KHOO et al.Therapeutic drug monitoring. 2007, Vol 29, Num 2, pp 231-235, issn 0163-4356, 5 p.Article

A Novel Agent with Histone Deacetylase Inhibitory Activity Attenuates Neointimal HyperplasiaRAHMATZADEH, M; LIU, H. B; KRISHNA, S. M et al.Cardiovascular drugs and therapy. 2014, Vol 28, Num 5, pp 395-406, issn 0920-3206, 12 p.Article

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?NOLAN, L; JOHNSON, P. W. M; GANESAN, A et al.British journal of cancer. 2008, Vol 99, Num 5, pp 689-694, issn 0007-0920, 6 p.Article

FK228 (depsipeptide) : a HDAC inhibitor with pleiotropic antitumor activitiesKONSTANTINOPOULOS, Panagiotis A; VANDOROS, Gerasimos P; PAPAVASSILIOU, Athanasios G et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 5, pp 711-715, issn 0344-5704, 5 p.Article

Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes : A comparative studyEDENS, R. Erik; DAGTAS, Selma; GILBERT, Kathleen M et al.International immunopharmacology. 2006, Vol 6, Num 11, pp 1673-1681, issn 1567-5769, 9 p.Article

Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781BANUELOS, Carmen A; BANATH, Judit P; MACPHAIL, Susan H et al.Clinical cancer research. 2007, Vol 13, Num 22, pp 6816-6826, issn 1078-0432, 11 p., 1Article

Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitorJIN HO KIM; JIN HEE SHIN; IL HAN KIM et al.International journal of radiation oncology, biology, physics. 2004, Vol 59, Num 4, pp 1174-1180, issn 0360-3016, 7 p.Article

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factorsSASAKAWA, Yuka; NAOE, Yoshinori; NOTO, Takahisa et al.Biochemical pharmacology. 2003, Vol 66, Num 6, pp 897-906, issn 0006-2952, 10 p.Article

Romidepsin for Cutaneous T-cell LymphomaMILES PRINCE, H; DICKINSON, Michael.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3509-3515, issn 1078-0432, 7 p.Article

Histone Deacetylase Inhibitor Enhances Recovery after AKICIANCIOLO COSENTINO, Chiara; SKRYPNYK, Nataliya I; DAVIDSON, Alan J et al.Journal of the American Society of Nephrology. 2013, Vol 24, Num 6, pp 943-953, issn 1046-6673, 11 p.Article

Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinasePARK, Jung-Hyun; JONG, Hyun-Soon; SANG GYUN KIM et al.Journal of molecular medicine (Berlin. Print). 2008, Vol 86, Num 1, pp 117-128, issn 0946-2716, 12 p.Article

Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitorSASAKAWA, Yuka; NAOE, Yoshinori; SOGO, Naoki et al.Biochemical pharmacology. 2005, Vol 69, Num 4, pp 603-616, issn 0006-2952, 14 p.Article

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorHAMBERG, Paul; WOO, Margaret M; DE JONGE, Maja et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 3, pp 805-813, issn 0344-5704, 9 p.Article

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serumPARISE, Robert A; HOLLERAN, Julianne L; BEUMER, Jan H et al.Journal of chromatography. B. 2006, Vol 840, Num 2, pp 108-115, issn 1570-0232, 8 p.Article

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitorACHARYA, Milin R; SPARREBOOM, Alex; SAUSVILLE, Edward A et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 3, pp 275-281, issn 0344-5704, 7 p.Article

Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitorsTAO LIU; LIU, Pei Y; TEE, Andrew E. L et al.European journal of cancer (1990). 2009, Vol 45, Num 10, pp 1846-1854, issn 0959-8049, 9 p.Article

The novel histone deacetylase inhibitor 4-Me2N-BAVAH differentially affects cell junctions between primary hepatocytesVINKEN, Mathieu; HENKENS, Tom; SNYKERS, Sarah et al.Toxicology (Amsterdam). 2007, Vol 236, Num 1-2, pp 92-102, issn 0300-483X, 11 p.Article

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancerSHAPIRO, Geoffrey I; FRANK, Richard; DANDAMUDI, Uday B et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 2, pp 555-562, issn 0344-5704, 8 p.Article

Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin ACRABB, Simon J; HOWELL, Melanie; JOHNSON, Peter W. M et al.Biochemical pharmacology. 2008, Vol 76, Num 4, pp 463-475, issn 0006-2952, 13 p.Article

Fadd and Skp2 are possible downstream targets of RUNX1-EVI1MAKI, Kazuhiro; SUGITA, Fusako; NAKAMURA, Yuka et al.International journal of hematology. 2013, Vol 97, Num 1, pp 83-91, issn 0925-5710, 9 p.Article

Epigenetics and cancer treatmentKRISTENSEN, Lasse Sommer; NIELSEN, Helene Myrtue; HANSEN, Lise Lotte et al.European journal of pharmacology. 2009, Vol 625, Num 1-3, pp 131-142, issn 0014-2999, 12 p.Article

Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors : Histone Deacetylase InhibitorsBUTLER, Kyle V; KOZIKOWSKI, Alan P.Current pharmaceutical design. 2008, Vol 14, Num 6, pp 505-528, issn 1381-6128, 24 p.Article

  • Page / 64